Revolution Medicines (RVMD) Non-Current Deffered Revenue (2019 - 2022)

Revolution Medicines' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $5.4 million for Q3 2022.

• In Q3 2022, Non-Current Deffered Revenue fell 44.02% year-over-year to $5.4 million; the TTM figure through Sep 2022 stood at $5.4 million (down 44.02% YoY), while the FY2021 annual figure was $6.6 million, down 22.5% from the prior year.
• Non-Current Deffered Revenue was $5.4 million for Q3 2022 at Revolution Medicines, up from $3.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.4 million in Q1 2020 to a low of $1.7 million in Q4 2019.
• Historically, Non-Current Deffered Revenue has averaged $7.6 million across 4 years, with a median of $7.9 million in 2021.
• The sharpest annual moves came in 2020 and 2022: Non-Current Deffered Revenue surged 387.13% in 2020, then plunged 49.65% in 2022.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $1.7 million in 2019, then soared by 387.13% to $8.5 million in 2020, then retreated by 22.5% to $6.6 million in 2021, then retreated by 17.57% to $5.4 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $5.4 million (Q3 2022), $3.8 million (Q2 2022), and $5.7 million (Q1 2022), per Business Quant data.